RIGImmune Inc.

RIGImmune Inc. is a leading biopharmaceutical research company dedicated to the development of groundbreaking RNA therapeutics. Focusing on preventing and treating severe respiratory diseases with significant unmet clinical needs, RIGImmune is at the forefront of innovative medical solutions.

Located at its primary address of 400 Farmington Avenue, Farmington, Connecticut 06032, US, RIGImmune is pioneering the advancement of stem-loop RNA therapeutics (SLRs). These novel oligonucleotides, combined with the company's proprietary nano-emulsion delivery technology platform, NEED™, enable targeted RNA compound delivery without lipid nanoparticle encapsulation. RIGImmune's commitment to research and development positions it as a key player in the biotechnology sector.

RIGImmune Inc. is committed to enhancing the innate immune response against viral respiratory diseases and developing treatments for cystic fibrosis. To further explore opportunities for collaboration and customized showcases, we invite the management team at RIGImmune to connect with us and create an exclusive company and product listing on our platform, enhancing your commercial development and reach.